Halozyme Therapeutics, Inc. (HALO)
107.74
-2.45
(-2.22%)
USD |
NASDAQ |
Sep 08, 12:54
Halozyme Therapeutics Price : 107.74 for Sept. 8, 2026
Price Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price Data
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 04, 2026 | 109.91 | 111.15 | 109.00 | 110.19 | 1.011M |
| Sep 03, 2026 | 109.84 | 111.15 | 108.74 | 110.76 | 1.890M |
| Sep 02, 2026 | 105.84 | 109.76 | 105.48 | 109.66 | 1.620M |
| Sep 01, 2026 | 107.45 | 108.53 | 106.87 | 107.72 | 1.059M |
| Aug 31, 2026 | 104.48 | 106.94 | 103.47 | 106.49 | 1.280M |
| Aug 28, 2026 | 106.45 | 106.80 | 104.70 | 105.35 | 1.682M |
| Aug 27, 2026 | 106.86 | 107.55 | 106.05 | 106.92 | 1.365M |
| Aug 26, 2026 | 109.32 | 109.66 | 107.00 | 107.06 | 1.706M |
| Aug 25, 2026 | 109.33 | 109.55 | 107.55 | 109.32 | 1.598M |
| Aug 24, 2026 | 108.00 | 109.10 | 106.87 | 108.64 | 2.091M |
| Aug 21, 2026 | 106.20 | 108.49 | 105.91 | 108.17 | 1.150M |
| Aug 20, 2026 | 106.41 | 107.44 | 105.20 | 106.12 | 1.578M |
| Aug 19, 2026 | 106.39 | 107.96 | 105.50 | 107.62 | 2.540M |
| Aug 18, 2026 | 102.95 | 105.11 | 102.38 | 104.89 | 1.955M |
| Aug 17, 2026 | 98.86 | 104.09 | 98.58 | 103.00 | 2.200M |
| Aug 14, 2026 | 100.35 | 100.83 | 98.13 | 98.66 | 1.659M |
| Aug 13, 2026 | 101.95 | 102.40 | 99.41 | 100.67 | 1.983M |
| Aug 12, 2026 | 102.00 | 102.58 | 100.47 | 101.79 | 3.651M |
| Aug 11, 2026 | 103.62 | 104.78 | 101.81 | 102.62 | 2.846M |
| Aug 10, 2026 | 102.67 | 104.77 | 101.11 | 102.62 | 4.935M |
| Aug 07, 2026 | 90.00 | 103.30 | 90.00 | 103.12 | 7.692M |
| Aug 06, 2026 | 84.15 | 86.00 | 82.60 | 85.76 | 2.704M |
| Aug 05, 2026 | 83.89 | 84.40 | 82.98 | 83.59 | 1.263M |
| Aug 04, 2026 | 82.78 | 83.89 | 81.75 | 83.23 | 1.575M |
| Aug 03, 2026 | 82.42 | 83.62 | 82.11 | 82.27 | 1.368M |
Price Definition
The price of a security measures the cost to purchase 1 share of a security. For a company, price can be multiplied by shares outstanding to find the market capitalization (value of the company).
Price Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price Benchmarks
| Incyte Corp. | 125.25 |
| AVITA Medical, Inc. | 10.61 |
| BioCryst Pharmaceuticals, Inc. | 9.26 |
| Neurocrine Biosciences, Inc. | 156.00 |
| Iovance Biotherapeutics, Inc. | 8.77 |
Price Related Metrics
| PE Ratio | 32.19 |
| PS Ratio | 7.837 |
| Price to Book Value | 85.60 |
| Price to Free Cash Flow | 16.17 |
| Earnings Yield | 3.11% |
| Market Cap | 12.29B |
| Operating PE Ratio | 13.81 |
| Normalized PE Ratio | 19.79 |